Large Inflow of Money Detected in Gilead Sciences

Gilead Sciences (GILD) stock had a bullish inflow of $159.75 million worth of trades on uptick and an outflow of $89.77 million in downticks on Monday. The total uptick to downtick ratio stood at 1.78. The net money flow into the stock was $69.98 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $66.22 million. An inflow of $4.95 million block trade was recorded on downticks. $71.17 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 14.37 in favor of the bulls. However, Gilead Sciences (GILD) stock traded down $0.01 , and reached $79.65, a drop of -0.01% over the previous day. On a weekly basis, the stock is -0.95%, over the previous weeks close.


Gilead Sciences Inc. has lost 0.11% in the last five trading days and dropped 8.1% in the last 4 weeks. Gilead Sciences Inc. has dropped 4.2% during the last 3-month period . Year-to-Date the stock performance stands at -20.46%.

Gilead Sciences (NASDAQ:GILD): The stock opened at $79.88 on Monday but the bulls could not build on the opening and the stock topped out at $80.09 for the day. The stock traded down to $79.43 during the day, due to lack of any buying support eventually closed down at $79.65 with a loss of -0.01% for the day. The stock had closed at $79.66 on the previous day. The total traded volume was 7,464,775 shares.

In a related news,The director officer (President and CEO) of Gilead Sciences Inc, Milligan John F sold 70,000 shares at $70.94 on August 1, 2016. The Insider selling transaction had a total value worth of $4,965,800. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.